Stockreport

AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

AVEO Pharmaceuticals, Inc.  (AVEO) 
Last aveo pharmaceuticals, inc. earnings: 3/16 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.aveooncology.com
PDF CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a rand [Read more]